1440
J. J. Hale et al. / Bioorg. Med. Chem. Lett. 11 (2001) 1437–1440
4. Centers for Disease Control and Prevention. HIV Surveil-
lance Supplemental Report 1999, 5, 1.
C. K.; Plagge, F.; Chu, D. T. W. Tetrahedron: Asymmetry 1997,
8, 883.
5. Dragic, T.; Litwin, V.; Allaway, G. P.; Martin, S. R.;
Huang, Y.; Nagashima, K. A.; Cayanan, C.; Maddon, P. J.;
Koup, R. A.; Moore, J. P.; Paxton, W. A. Nature 1996, 381,
667.
6. Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.;
Burkhart, M.; Di Marzio, P.; Marmon, S.; Sutton, R. E.; Hill,
C. M.; Davis, C. B.; Peiper, S. C.; Schall, T. J.; Littman, D. R.;
Landau, N. R. Nature 1996, 381, 661.
7. Samson, M.; Libert, F.; Doranz, B. J.; Rucker, J.; Liesnard,
C.; Farber, C.-M.; Saragosti, S.; Lapoumeroulie, C.; Cognaux,
J.; Forceille, C.; Muyldermans, G.; Verhofstede, C.; Burton-
boy, G.; Georges, M.; Imai, T.; Rana, S.; Yi, Y.; Smyth, R. J.;
Collman, R. G.; Doms, R. W.; Vassart, G.; Parmentier, M.
Nature 1996, 382, 722.
8. Liu, R.; Paxton, W. A.; Choe, S.; Ceradini, D.; Martin,
S. R.; Horuk, R.; MacDonald, M. E.; Stuhlmann, H.; Koup,
R. A.; Landau, N. R. Cell 1996, 86, 367.
9. Kilby, J. M. Expert Opin. Invest. Drugs 1999, 8, 1157.
10. Baba, M.; Nishimura, O.; Kanzaki, N.; Okamoto, M.;
Sawada, H.; Iizawa, Y.; Shiraishi, M.; Aramaki, Y.; Okonogi,
K.; Ogawa, Y.; Meguro, K.; Fujino, M. Proc. Natl. Acad. Sci.
U.S.A. 1999, 96, 5698.
11. Baroudy, B. Abstract A17. 7th Conference of Retro-
viruses and Opportunistic Infections, San Francisco, CA,
USA, Jan 31–Feb3, 2000.
12. Dorn, C. P.; Finke, P. E.; Oates, B.; Budhu, R. J.;
Mills, S. G.; MacCoss, M.; Malkowitz, L.; Springer, M. S.;
Daugherty, B. L.; Gould, S. L.; DeMartino, J. A.; Sici-
liano, S. J.; Carella, A.; Carver, G.; Holmes, K.; Danzeisen,
R.; Hazuda, D.; Kessler, J.; Lineberger, J.; Miller, M.;
Schlief, W. A.; Emini, E. A. Bioorg. Med. Chem. Lett.
2001, 11, 259.
13. Finke, P. E.; Meurer, L. C.; Oates, B.; Mills, S. G.; Mac-
Coss, M.; Malkowitz, L.; Springer, M. S.; Daugherty, B. L.;
Gould, S. L.; DeMartino, J. A.; Siciliano, S. J.; Carella, A.;
Carver, G.; Holmes, K.; Danzeisen, R.; Hazuda, D.; Kessler,
J.; Lineberger, J.; Miller, M.; Schlief, W. A.; Emini, E. A.
Bioorg. Med. Chem. Lett. 2001, 11, 265.
19. Kise, N.; Mashiba, S.-I.; Ueda, N. J. Org. Chem. 1998, 63,
7931.
20. [125I]-MIP-1a (2200 Ci/mmol) was purchased from NEN
Life Science Products. Test compound (5 mL in DMSO), [125I]-
MIP-1a (6 pmol, ꢄ0.01 mCi) and 0.1 mg of Chinese hamster
ovary (CHO) CCR5 membrane are combined in assay buffer
(50 mM Hepes, 0.5% BSA, 5 mM MgCl2, 1 mM CaCl2, pH 7.2
w/ protease inhibitor cocktail (0.1 mM PMSF, 0.01 mM phos-
phoramidon and 10 mg/mL leupeptin, aprotinin and chymo-
statin) to a final volume of 250 mL. The assay mixture is
incubated for 240 min at 24 ꢀC (on a plate shaker) and then
harvested on a GF/C glass fiber filter plate pre-treated with
0.33% polyethylenimine (PEI). The filter plate is subsequently
washed twice with 250 mL of Hepes wash buffer (25 mM
Hepes, 0.5 M NaCl, 0.01% NaN3, pH 7.2) and counted on
Packard Topcount by adding 30 mL Microscint O to each well.
IC50 values were calculated by nonlinear least-squares regres-
sion analysis of the mean data.
21. Doranz, B. J.; Baik, S. S. W.; Doms, R. W. J. Virol. 1999,
73, 10346.
22. Lee, B.; Sharron, M.; Blanpain, C.; Doranz, B.; Vakili, J.;
Setoh, P.; Berg, E.; Liu, G.; Guy, H. R.; Durell, S. R.; Par-
mentier, M.; Chang, C. N.; Price, K.; Tsang, M.; Doms, R. W.
J. Biol. Chem. 1999, 274, 9617.
23. Levy, J. A.; Mackewitz, C. E.; Barker, E. Immunol. Today
1996, 17, 217.
24. Coochi, F.; DeVico, A. L.; Garzino-Demo, A.; Arya,
S. K.; Gallo, R. C.; Lusso, P. Science 1995, 270, 1811.
25. Gan, F. C. The Scientist 1990, 4, 24.
26. Chinese hamster ovary cells stably transfected with human
CCR5 were seeded onto Transwell cell capsule cups (Molec-
ular Devices) at a density of 0.33ꢂ106 cells/mL/cup in MEM
alpha medium. Following overnight culture, the capsules were
transferred to microphysiometer sensor chambers (Cyto-
sensor, Molecular Devices) and allowed to equilibrate for 30
min–2 h during which time they were perfused with running
medium [1 mM phosphate-buffered RPMI-1640 medium, pH
7.4 (Molecular Devices)+0.1 BSA]. Once stable acidification
rates were established, the cells were exposed to either 1 nM
MIP-1a or 1 mM 18 for 6 min at a flow rate of 0.1 mL/min of
running medium. Perfusion was stopped at 2 min intervals,
during which time acidification rates were measured for 30 s.
The data collected was normalized using the Cytosensor
microphysiometer software. Compound 18 at a concentration
of 1 mM was found to elicit 11% of the initial response of
MIP-1a at its EC50 (1–2 nM).
14. Padwa, A.; Dent, W. J. Org. Chem. 1987, 52, 235.
15. Chen, M.-H.; Abraham, J. A. Tetrahedron Lett. 1996, 37,
5233.
16. Chen, M.-H.; Pollard, P. P.; Patchett, A. A. Bioorg. Med.
Chem. Lett. 1999, 9, 1261.
17. Karlsson, S.; Han, F.; Hogberg, H.-E.; Caldirola, P.
Tetrahedron: Asymmetry 1999, 10, 2605.
18. Ma, Z.; Wang, S.; Cooper, C. S.; Fung, A. K. L.; Lynch,